Showing results (281-290 of 340) with videos related to
Sort By:
Pageof 34
Journal of the American Society of Nephrology : JASN|May 3, 2014
Effects of lowering LDL cholesterol on progression of kidney diseaseRichard Haynes, David Lewis, Jonathan Emberson, et al.Diabetes, Obesity & Metabolism|June 19, 2024
Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trialKathryn Cardoza, Amy Kang, Brendan Smyth, et al.Diabetes, Obesity & Metabolism|November 13, 2020
Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trialJeroen V Koomen, Jasper Stevens, George Bakris, et al.Frontiers in Pharmacology|May 24, 2021
Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building MeetingElisabeth Bakker, Peter G M Mol, João Nabais, et al.Diabetes, Obesity & Metabolism|December 17, 2016
Comparison of exposure response relationship of atrasentan between North American and Asian populationsHiddo J L Heerspink, Hirofumi Makino, Dennis Andress, et al.Clinical Pharmacology and Therapeutics|December 18, 2020
Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney DiseaseJeroen V Koomen, Jasper Stevens, George Bakris, et al.Journal of the American Society of Nephrology : JASN|April 12, 2014
The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathyDick de Zeeuw, Blai Coll, Dennis Andress, et al.Journal of the American Society of Nephrology : JASN|October 1, 2020
Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A PostHoc Analysis from the CREDENCE TrialMegumi Oshima, Brendon L Neuen, JingWei Li, et al.Clinical Journal of the American Society of Nephrology : CJASN|July 9, 2015
Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic NephropathyDonald E Kohan, Hiddo J Lambers Heerspink, Blai Coll, et al.Lancet (London, England)|December 18, 2023
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trialKatherine R Tuttle, Sibylle J Hauske, Maria Eugenia Canziani, et al.Pageof 34